A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults

New England Journal of Medicine

Volumn 362, Issue 9, 2010, Pages 812-822

  French, Neil ^a,c   Gordon, Stephen B ^a,d   Mwalukomo, Thandie ^b   White, Sarah A ^a   Mwafulirwa, Gershom ^a   Longwe, Herbert ^a   Mwaiponya, Martin ^b   Zijlstra, Eduard E ^b   Molyneux, Malcolm E ^a,d   Gilks, Charles F ^e  

^a MALAWI LIVERPOOL WELLCOME TRUST CLINICAL RESEARCH PROGRAMME   (Malawi)

^b UNIVERSITY OF MALAWI   (Malawi)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; EFAVIRENZ; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; PLACEBO; PNEUMOCOCCUS VACCINE; STAVUDINE; ZIDOVUDINE; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; VACCINE;

ADOLESCENT; ADULT; AFRICA; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FEVER; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; UNSPECIFIED SIDE EFFECT; VACCINATION; VACCINE FAILURE; VIRUS LOAD; AIDS RELATED COMPLEX; CLASSIFICATION; INTENTION TO TREAT ANALYSIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTOR; STREPTOCOCCUS PNEUMONIA;

ADOLESCENT; ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; RISK FACTORS; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 77649329574     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0903029     Document Type: Article

References (30)

1. Gilks CF, Ojoo SA, Ojoo JC, et al. Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya. Lancet 1996;347:718-23.
2. Klugman KP, Madhi SA, Feldman C. HIV and pneumococcal disease. Curr Opin Infect Dis 2007;20:11-5.
3. Janoff EN, Breiman RF, Daley CL, Hopewell PC. Pneumococcal disease during HIV infection: epidemiologic, clinical, and immunologic perspectives. Ann Intern Med 1992;117:314-24.
4. Heffernan RT, Barrett NL, Gallagher KM, et al. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. J Infect Dis 2005;191:2038-45.
5. French N, Nakiyingi J, Carpenter LM, et al. 23-Valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000;355: 2106-11.
6. Grau I, Pallares R, Tubau F, et al. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med 2005;165:1533-40.
7. Scarborough M, Gordon SB, Whitty CJ, et al. Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa. N Engl J Med 2007;357:2441-50.
8. 23-Valent pneumococcal polysaccharide vaccine: WHO position paper. Wkly Epidemiol Rec 2008;83:373-84.
9. Masur H, Kaplan JE, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons - 2002: recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 2002;137:435-78.
10. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000; 19:187-95.
11. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003;349:1341-8.
12. O'Brien KL, Moulton LH, Reid R, et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 2003;362:355-61.
13. Cutts FT, Zaman SM, Enwere G, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005;365: 1139-46.
14. Madhi SA, Adrian P, Kuwanda L, et al. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine 2007;25:2451-7.
15. Feikin DR, Elie CM, Goetz MB, et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine 2001;20: 545-53.
16. Miiro G, Kayhty H, Watera C, et al. Conjugate pneumococcal vaccine in HIVinfected Ugandans and the effect of past receipt of polysaccharide vaccine. J Infect Dis 2005;192:1801-5.
17. Gordon SB, Kayhty H, Molyneux ME, et al. Pneumococcal conjugate vaccine is immunogenic in lung fluid of HIV-infected and immunocompetent adults. J Allergy Clin Immunol 2007;120:208-10.
18. Gordon SB, Kanyanda S, Walsh AL, et al. Poor potential coverage for 7-valent pneumococcal conjugate vaccine, Malawi. Emerg Infect Dis 2003;9:747-9.
19. Gordon SB, Chaponda M, Walsh AL, et al. Pneumococcal disease in HIV-infected Malawian adults: acute mortality and long-term survival. AIDS 2002;16:1409-17.
20. Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006;368:1495-502.
21. Klugman KP, Cutts FT, Adegbola RA, et al. Meta-analysis of the efficacy of conjugate vaccines against invasive pneumococcal disease. In: Siber G, Klugman KP, Makela H, eds. Pneumococcal vaccines: the impact of conjugate vaccine. Washington, DC: ASM Press, 2008:317-26.
22. Janoff EN, Rubins JB. Invasive pneumococcal disease in the immunocompromised host. Microb Drug Resist 1997;3: 215-32.
23. Piantadosi S. Clinical trials: a methodologic perspective. New York: John Wiley, 1997:248.
24. Brichacek B, Swindells S, Janoff EN, Pirrucello S, Stevenson M. Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. J Infect Dis 1996; 174:1191-9.
25. Anglaret X, Toure S, Gourvellec G, et al. Impact of vital status investigation procedures on estimates of survival in cohorts of HIV-infected patients from Sub-Saharan Africa. J Acquir Immune Defic Syndr 2004;35:320-3.
26. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and highincome countries. Lancet 2006;367:817-24. [Erratum, Lancet 2006;367:1902.]
27. Yu JK, Chen SC, Wang KY, et al. True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi. Bull World Health Organ 2007;85: 550-4.
28. Brinkhof MW, Dabis F, Myer L, et al. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ 2008;86:559-67.
29. Flannery B, Heffernan RT, Harrison LH, et al. Changes in invasive pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Ann Intern Med 2006; 144:1-9.
30. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003;348:1737-46.